Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial

Jul 31, 2026 10:02 PM - 1 month ago 722

Topline

Novo Nordisk shares plunged connected Friday, erasing much than $30 cardinal successful marketplace worth aft the Danish drugmaker said a late-stage experimental supplier grounded successful a ample study, drafting disapproval from analysts who said the patient missed an opportunity to grow beyond its weight-loss offerings.

Analysts were captious of the Ozempic maker’s grounded proceedings for a caller experimental drug.

NurPhoto via Getty Images

Key Facts

Shares of Novo Nordisk dropped 9.3% to astir $46.70 arsenic of Friday morning, marking the stock’s largest intraday nonaccomplishment since February and a 10.6% diminution truthful acold this year.

Novo Nordisk reported Friday its ziltivekimab “did not achieve” goals to trim awesome adverse cardiovascular events for illustration a bosom onslaught aliases changeable successful a late-stage objective trial, and it did not disclose really overmuch the supplier reduced risks.

Jeffries analysts wrote successful a statement that ziltivekimab would person needed to show astatine slightest a 20% consequence reduction, and the proceedings results were “strategically negative” arsenic they efficaciously erased a maturation opportunity for Novo Nordisk’s business beyond its Ozempic and Wegovy marketplace that could person been worthy much than $10 cardinal annually.

Goldman Sachs analysts praised the drug’s imaginable up of the proceedings results, penning ziltivekimab could person been the instauration for Novo Nordisk to build a franchise successful cardiovascular illness attraction and relieve imaginable risks to sales, which are mostly reliant connected Ozempic and Wegovy.

big number

$30.7 billion. That’s really overmuch was trim from Novo Nordisk’s marketplace capitalization arsenic of Friday’s stock price, lowering from $229.2 cardinal to $198.5 billion, marking a astir 69% diminution since hitting an all-time precocious of $635.7 cardinal successful June 2024.

key background

Novo Nordisk, contempt the occurrence of its Ozempic and Wegovy narcotics successful caller years, has worked to grow connected its different businesses to bolster sales. The patient has moved to summation the GLP-1 marketplace by expanding into pill versions of its medications, and Novo Nordisk has since launched a Wegovy pill successful the United Arab Emirates and the U.K., pinch plans to waste successful the U.S. and globally.

tangent

Novo Nordisk fought pinch Eli Lilly earlier this month, accusing the rival GLP-1 shaper of “deceptive” advertizing that Novo Nordisk said relied connected outdated information to make its products look little effective. The Ozempic shaper said it looked to resoluteness the conflict retired of court, but “Lilly refused, calling its advertizing ‘truthful’ and ‘transparent,’” according to tribunal documents. The mobility besides asks the tribunal to require Lilly to rumor corrective advertizing that indicates its advertisement campaigns had “planted mendacious beliefs successful consumers’ minds.”